The IGF-I generation test revisited: A marker of GH sensitivity

C. K. Buckway, J. Guevara-Aguirre, K. L. Pratt, C. P. Burren, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

IGF-I generation tests were developed over 20 yr ago and are currently used in differentiating GH insensitivity (GHI) from other disorders characterized by low serum IGF-I. Nevertheless, generation tests have never been adequately characterized, and insufficient normative data are available. One hundred and ninety-eight subjects [including normal subjects; subjects with GHI, GH deficiency (GHD), and idiopathic short stature (ISS); and heterozygotes for the E180 splice GH receptor mutation] were randomized to self-administration of either a high (0.05 mg/kg·d) or a low (0.025 mg/kg·d) dose of GH for 7 d. After a 2-wk washout period, they received the alternate dose. Samples were collected on d 1, 5, and 8 of each treatment period. In normal individuals, IGF-I generation was GH dependent at all ages, and little advantage was observed in using the higher dose of GH or extending beyond the d 5 sample. Some GHD patients had IGF-I levels, both baseline and stimulated, that overlapped levels in the verified GHI patients. Subjects heterozygous for the E180 GH receptor splice mutation did not show a decreased responsiveness to GH. ISS patients had low-normal IGF-I levels that did not stimulate beyond the baseline normative ranges for age. These data provide the first large scale effort to provide preliminary normative IGF generation data and evaluate the GH sensitivity of patients with GHI, GHD, and ISS.

Original languageEnglish (US)
Pages (from-to)5176-5183
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume86
Issue number11
DOIs
StatePublished - 2001

Fingerprint

Insulin-Like Growth Factor I
Mutation
Self Administration
Heterozygote
Serum
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Buckway, C. K., Guevara-Aguirre, J., Pratt, K. L., Burren, C. P., & Rosenfeld, R. R. (2001). The IGF-I generation test revisited: A marker of GH sensitivity. Journal of Clinical Endocrinology and Metabolism, 86(11), 5176-5183. https://doi.org/10.1210/jc.86.11.5176

The IGF-I generation test revisited : A marker of GH sensitivity. / Buckway, C. K.; Guevara-Aguirre, J.; Pratt, K. L.; Burren, C. P.; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 11, 2001, p. 5176-5183.

Research output: Contribution to journalArticle

Buckway, CK, Guevara-Aguirre, J, Pratt, KL, Burren, CP & Rosenfeld, RR 2001, 'The IGF-I generation test revisited: A marker of GH sensitivity', Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5176-5183. https://doi.org/10.1210/jc.86.11.5176
Buckway, C. K. ; Guevara-Aguirre, J. ; Pratt, K. L. ; Burren, C. P. ; Rosenfeld, Ronald (Ron). / The IGF-I generation test revisited : A marker of GH sensitivity. In: Journal of Clinical Endocrinology and Metabolism. 2001 ; Vol. 86, No. 11. pp. 5176-5183.
@article{d79921773d0b43abbdd87c31ace2c5b8,
title = "The IGF-I generation test revisited: A marker of GH sensitivity",
abstract = "IGF-I generation tests were developed over 20 yr ago and are currently used in differentiating GH insensitivity (GHI) from other disorders characterized by low serum IGF-I. Nevertheless, generation tests have never been adequately characterized, and insufficient normative data are available. One hundred and ninety-eight subjects [including normal subjects; subjects with GHI, GH deficiency (GHD), and idiopathic short stature (ISS); and heterozygotes for the E180 splice GH receptor mutation] were randomized to self-administration of either a high (0.05 mg/kg·d) or a low (0.025 mg/kg·d) dose of GH for 7 d. After a 2-wk washout period, they received the alternate dose. Samples were collected on d 1, 5, and 8 of each treatment period. In normal individuals, IGF-I generation was GH dependent at all ages, and little advantage was observed in using the higher dose of GH or extending beyond the d 5 sample. Some GHD patients had IGF-I levels, both baseline and stimulated, that overlapped levels in the verified GHI patients. Subjects heterozygous for the E180 GH receptor splice mutation did not show a decreased responsiveness to GH. ISS patients had low-normal IGF-I levels that did not stimulate beyond the baseline normative ranges for age. These data provide the first large scale effort to provide preliminary normative IGF generation data and evaluate the GH sensitivity of patients with GHI, GHD, and ISS.",
author = "Buckway, {C. K.} and J. Guevara-Aguirre and Pratt, {K. L.} and Burren, {C. P.} and Rosenfeld, {Ronald (Ron)}",
year = "2001",
doi = "10.1210/jc.86.11.5176",
language = "English (US)",
volume = "86",
pages = "5176--5183",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - The IGF-I generation test revisited

T2 - A marker of GH sensitivity

AU - Buckway, C. K.

AU - Guevara-Aguirre, J.

AU - Pratt, K. L.

AU - Burren, C. P.

AU - Rosenfeld, Ronald (Ron)

PY - 2001

Y1 - 2001

N2 - IGF-I generation tests were developed over 20 yr ago and are currently used in differentiating GH insensitivity (GHI) from other disorders characterized by low serum IGF-I. Nevertheless, generation tests have never been adequately characterized, and insufficient normative data are available. One hundred and ninety-eight subjects [including normal subjects; subjects with GHI, GH deficiency (GHD), and idiopathic short stature (ISS); and heterozygotes for the E180 splice GH receptor mutation] were randomized to self-administration of either a high (0.05 mg/kg·d) or a low (0.025 mg/kg·d) dose of GH for 7 d. After a 2-wk washout period, they received the alternate dose. Samples were collected on d 1, 5, and 8 of each treatment period. In normal individuals, IGF-I generation was GH dependent at all ages, and little advantage was observed in using the higher dose of GH or extending beyond the d 5 sample. Some GHD patients had IGF-I levels, both baseline and stimulated, that overlapped levels in the verified GHI patients. Subjects heterozygous for the E180 GH receptor splice mutation did not show a decreased responsiveness to GH. ISS patients had low-normal IGF-I levels that did not stimulate beyond the baseline normative ranges for age. These data provide the first large scale effort to provide preliminary normative IGF generation data and evaluate the GH sensitivity of patients with GHI, GHD, and ISS.

AB - IGF-I generation tests were developed over 20 yr ago and are currently used in differentiating GH insensitivity (GHI) from other disorders characterized by low serum IGF-I. Nevertheless, generation tests have never been adequately characterized, and insufficient normative data are available. One hundred and ninety-eight subjects [including normal subjects; subjects with GHI, GH deficiency (GHD), and idiopathic short stature (ISS); and heterozygotes for the E180 splice GH receptor mutation] were randomized to self-administration of either a high (0.05 mg/kg·d) or a low (0.025 mg/kg·d) dose of GH for 7 d. After a 2-wk washout period, they received the alternate dose. Samples were collected on d 1, 5, and 8 of each treatment period. In normal individuals, IGF-I generation was GH dependent at all ages, and little advantage was observed in using the higher dose of GH or extending beyond the d 5 sample. Some GHD patients had IGF-I levels, both baseline and stimulated, that overlapped levels in the verified GHI patients. Subjects heterozygous for the E180 GH receptor splice mutation did not show a decreased responsiveness to GH. ISS patients had low-normal IGF-I levels that did not stimulate beyond the baseline normative ranges for age. These data provide the first large scale effort to provide preliminary normative IGF generation data and evaluate the GH sensitivity of patients with GHI, GHD, and ISS.

UR - http://www.scopus.com/inward/record.url?scp=0035176304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035176304&partnerID=8YFLogxK

U2 - 10.1210/jc.86.11.5176

DO - 10.1210/jc.86.11.5176

M3 - Article

C2 - 11701674

AN - SCOPUS:0035176304

VL - 86

SP - 5176

EP - 5183

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -